《新股消息》固生堂(02273.HK)上限29元定價 一手中籤率60%
內地中醫醫療健康服務提供商固生堂(02273.HK)公佈招股結果,每股發售價定爲29元,爲上限定價(招股價介乎25.8至29元),香港公開發售部分錄得超額認購約1.84倍,國際發售亦錄超購3.4倍。每手100股計,一手中籤率60%,認購兩手即200股可穩獲一手。該股將於明日(10日)掛牌。聯席保薦人爲美銀證券及海通國際。
公司上市獲四名基石投資者合共認購1,124.13萬股,佔緊隨全球發售完成後的股本約4.88%,包括Foresight Funds、Boyu、Sage Partners及UBS AM Singapore。
是次上市料淨集資約7.05億元,約69.8%用於拓展線上線下業務,加強線上線下業務融合;約9.6%用於加強研發能力,包括院內製劑以及中醫解決方案包的研發;約9.6%將用於加強供應鏈能力,包括根據業務擴張計劃升級現有煎藥中心及建立新煎藥中心,並根據業務需要在中長期內建立自有GMP廠;約4.9%用於營銷及品牌活動;及約6%用於營運資金和一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.